Two distinct HDAC inhibitors, butyrate and SAHA, induced caspase-3 activation and cell death in multiple human cancer cell lines; however, Apaf-1 knockout, overexpression of Bcl-xL, and pharmacological inhibition of caspase activity did not prevent SAHA and butyrate-induced cell death. Here, HDAC9 is linked to cancer.